| Drug Name |
Triazolam |
| Drug ID |
BADD_D02277 |
| Description |
Withdrawn in the United Kingdom due to risk of psychiatric adverse drug reactions. This drug continues to be available in the U.S. Internationally, triazolam is a Schedule IV drug under the Convention on Psychotropic Substances. |
| Indications and Usage |
For the short-term treatment of insomnia. |
| Marketing Status |
Prescription; Discontinued |
| ATC Code |
N05CD05 |
| DrugBank ID |
DB00897
|
| KEGG ID |
D00387
|
| MeSH ID |
D014229
|
| PubChem ID |
5556
|
| TTD Drug ID |
D0U3LS
|
| NDC Product Code |
0009-0017; 55289-787; 67763-128; 0054-4858; 0009-5188; 50742-645; 59762-3718; 50742-646; 71335-1876; 59762-3717; 50090-4733; 12828-0041; 0054-4859; 43063-996; 50090-0522; 42816-0017; 43353-451; 63629-2956 |
| Synonyms |
Triazolam | U-33,030 | U 33,030 | U33,030 | Halcion | Trilam | Apo-Triazo | Apo Triazo | Gen-Triazolam | Gen Triazolam |
